BiotechTube
Abpro

Abpro

Woburn, United States· Est.
abpro.co
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $230M

Overview

Abpro is a US-based biotech company founded in 2007, specializing in antibody discovery and engineering. It has transitioned to a publicly traded entity and is advancing a pipeline of bispecific and multispecific antibody candidates, with a lead T-cell engager program, ABP-102/CT-P72, in preclinical development for HER2-positive cancers. The company's strategy relies on its proprietary technology platforms and strategic collaborations, such as with Celltrion, to develop potential best-in-class therapies.

Oncology

Technology Platform

Proprietary DiversImmune® platform for antibody discovery and MultiMab™ platform for engineering multispecific antibodies.

Funding History

4
Total raised:$230M
PIPE$125M
Series B$70M
Series A$30M
Seed$5M

Opportunities

The large and growing market for bispecific antibodies in oncology, particularly for solid tumors like HER2-positive cancers, presents a significant opportunity.
Successful validation of its lead candidate could position Abpro as an attractive partner or acquisition target for larger biopharma companies.

Risk Factors

Abpro faces high clinical development risk as its lead candidate is preclinical, financial risk due to its pre-revenue status and future capital needs, and intense competition in the bispecific antibody and HER2-targeted therapy space from well-resourced companies.

Competitive Landscape

Abpro competes in the crowded bispecific T-cell engager and HER2-targeted therapy markets against large pharma (e.g., Roche, Amgen) and numerous biotech companies. Differentiation will require demonstrating superior efficacy, safety, or dosing convenience with its tetravalent MultiMab™-engineered constructs.

More companies in Biologics / Biosimilars →More companies in United States →